Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines

In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to investigate the role of surface charge of NPs for developing drug delivery system for non-small-cell lung cancer (NSCLC). The developed NPs were evalu...

Full description

Saved in:
Bibliographic Details
Published inSaudi journal of biological sciences Vol. 28; no. 9; pp. 5065 - 5073
Main Author Alshetaili, Abdullah S.
Format Journal Article
LanguageEnglish
Published Riyadh, Saudi Arabia Elsevier B.V 01.09.2021
Saudi Biological Society
Elsevier
Subjects
Chitosan
Gefitinib
MTT assay
Nanoparticles
Original
PLGA
Nanoparticles
PLGA
Chitosan
Gefitinib
MTT assay
Online AccessGet full text

Cover

Abstract In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to investigate the role of surface charge of NPs for developing drug delivery system for non-small-cell lung cancer (NSCLC). The developed NPs were evaluated for their size, PDI, zeta potential (ZP), drug entrapment, drug loading, DSC, FTIR, XRD, in vitro release profile, and morphology. The anti-cancer activity of GFT loaded PLGA NPs and GFT loaded CS-PLGA-NPs were examined in human A549 lung cancer cell lines. In vitro release studies of GFT-CS-PLGA-NPs showed more sustained release in comparison to GFT-PLGA-NPs due surface charge attraction of chitosan. In addition, viability of A549 cells decreases significantly with the increasing concentration of GFT-PLGA NPs and GFT-CS-PLGA-NPs when compared to that of pure GFT and blank PLGA NPs. In addition, the microscopic analysis and counting of viable cells also validate the cytotoxicity of the developed NPs. This investigation proved that the developed NPs would be efficient carriers to deliver GFT with improved efficacy against NSCLC.
AbstractList In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to investigate the role of surface charge of NPs for developing drug delivery system for non-small-cell lung cancer (NSCLC). The developed NPs were evaluated for their size, PDI, zeta potential (ZP), drug entrapment, drug loading, DSC, FTIR, XRD, in vitro release profile, and morphology. The anti-cancer activity of GFT loaded PLGA NPs and GFT loaded CS-PLGA-NPs were examined in human A549 lung cancer cell lines. In vitro release studies of GFT-CS-PLGA-NPs showed more sustained release in comparison to GFT-PLGA-NPs due surface charge attraction of chitosan. In addition, viability of A549 cells decreases significantly with the increasing concentration of GFT-PLGA NPs and GFT-CS-PLGA-NPs when compared to that of pure GFT and blank PLGA NPs. In addition, the microscopic analysis and counting of viable cells also validate the cytotoxicity of the developed NPs. This investigation proved that the developed NPs would be efficient carriers to deliver GFT with improved efficacy against NSCLC.
In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to investigate the role of surface charge of NPs for developing drug delivery system for non-small-cell lung cancer (NSCLC). The developed NPs were evaluated for their size, PDI, zeta potential (ZP), drug entrapment, drug loading, DSC, FTIR, XRD, in vitro release profile, and morphology. The anti-cancer activity of GFT loaded PLGA NPs and GFT loaded CS-PLGA-NPs were examined in human A549 lung cancer cell lines. In vitro release studies of GFT-CS-PLGA-NPs showed more sustained release in comparison to GFT-PLGA-NPs due surface charge attraction of chitosan. In addition, viability of A549 cells decreases significantly with the increasing concentration of GFT-PLGA NPs and GFT-CS-PLGA-NPs when compared to that of pure GFT and blank PLGA NPs. In addition, the microscopic analysis and counting of viable cells also validate the cytotoxicity of the developed NPs. This investigation proved that the developed NPs would be efficient carriers to deliver GFT with improved efficacy against NSCLC.
Author Alshetaili, Abdullah S.
Author_xml – sequence: 1
  givenname: Abdullah S.
  surname: Alshetaili
  fullname: Alshetaili, Abdullah S.
  email: a.alshetaili@psau.edu.sa
  organization: Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
BookMark eNp9kk2LUzEYhYOMOJ3RP-BCsnTTmuQmdxIQoQxaBwq6UHAX8vGmTblN6k06WvDHm06rMhs3CeQ95wk5OVfoIuUECL2kZEYJ7d9sZmVjy4wRRmdEzAgTT9CEMdpNbyjpL9CEdlRNRc--XaKrUjaE9LKT9Bm67DjveyL5BP1aQIg1pmjxkI0Hjz8vF3NsksduHWsuJmGXTf0zSCblnRlrdAMU_CPWNd6aVYohNoU71Fzzz-hiPWCzMjGViueCKzzs0wo7kxyM2MEw4CEmKM_R02CGAi_O-zX6-uH9l9uP0-Wnxd3tfDl1gtE67QKxzAZhufQ9VZL2lHouO8uZN8F2DminZA-B3gjLQAlJQmir94ZSYUl3je5OXJ_NRu_GuDXjQWcT9cNBHlf6_CTNqQpEBcVNIJw6ohqVgFHWd9ZJrhrr3Ym129steAepjmZ4BH08SXGtV_leH6MnkjbA6zNgzN_3UKrexnLMxCTI-6KZ6CUTnD1I2UnqxlzKCOHvNZToYwX0Rh8roI8V0EToVoFmenUyQVNCMP88vFkEa4K3Z0GL_D7CqIuL0L7GxxFcbZnE__F_Ay83xhM
CitedBy_id crossref_primary_10_3390_polym13142272
crossref_primary_10_3390_polym14122459
crossref_primary_10_2174_2210303113666221226092547
crossref_primary_10_1080_10837450_2023_2206668
crossref_primary_10_1080_17458080_2023_2193400
crossref_primary_10_1021_acsomega_3c01375
crossref_primary_10_1016_j_matdes_2022_110824
crossref_primary_10_1016_j_ijbiomac_2024_132888
crossref_primary_10_1016_j_jddst_2023_104196
crossref_primary_10_1016_j_matpr_2023_04_238
crossref_primary_10_1080_15583724_2024_2323943
crossref_primary_10_1016_j_jsps_2022_11_004
crossref_primary_10_1016_j_onano_2023_100183
crossref_primary_10_1016_j_procbio_2022_04_003
crossref_primary_10_1016_j_ijpharm_2023_123017
crossref_primary_10_3390_pr9071210
crossref_primary_10_1002_cnma_202300530
crossref_primary_10_1016_j_bioadv_2022_213002
crossref_primary_10_1016_j_jddst_2023_104554
crossref_primary_10_1007_s10853_024_09754_7
crossref_primary_10_1016_j_ijbiomac_2023_126471
crossref_primary_10_1039_D2TB00469K
crossref_primary_10_1016_j_jddst_2024_105786
crossref_primary_10_1016_j_jddst_2022_103865
crossref_primary_10_1080_1539445X_2023_2199419
crossref_primary_10_3390_ph16111549
crossref_primary_10_1080_02652048_2023_2244095
crossref_primary_10_1049_nbt2_12139
crossref_primary_10_1080_09205063_2024_2328421
crossref_primary_10_2174_1567201819666220112121115
crossref_primary_10_1016_j_cclet_2023_109384
crossref_primary_10_1016_j_colsurfa_2022_129629
crossref_primary_10_3390_pharmaceutics14102021
crossref_primary_10_3390_ma16155364
crossref_primary_10_3390_pr10071329
crossref_primary_10_1016_j_ijpharm_2023_123703
crossref_primary_10_2147_IJN_S452989
crossref_primary_10_1016_j_ijpharm_2023_123160
crossref_primary_10_1007_s40199_023_00495_7
crossref_primary_10_1007_s00289_022_04436_3
crossref_primary_10_1016_j_jddst_2023_104523
crossref_primary_10_1080_17458080_2022_2060501
crossref_primary_10_3390_app131910859
Cites_doi 10.3389/fphar.2018.01260
10.1007/s13346-016-0295-x
10.1016/j.ejps.2017.02.002
10.1016/j.ejps.2020.105352
10.3390/md18120605
10.1016/j.omtn.2020.07.027
10.1016/j.canlet.2020.09.003
10.1016/j.nano.2007.03.006
10.1016/j.ijbiomac.2018.06.043
10.1016/j.jtho.2019.09.008
10.1016/j.jcou.2017.04.015
10.1016/j.toxrep.2014.11.002
10.1016/j.phrs.2020.104934
10.2147/IJN.S195048
10.3390/pharmaceutics11090469
10.2147/IJN.S237314
10.1016/j.jconrel.2007.03.012
10.1016/j.mbs.2019.108293
10.1016/j.bioorg.2020.103726
10.1016/j.colsurfb.2015.11.033
10.1080/10717544.2017.1384862
10.3892/mmr.2021.11964
10.1080/21691401.2018.1457039
10.1186/s12951-014-0043-7
10.3389/fphar.2017.00844
10.1016/j.molliq.2017.11.081
10.1016/j.lungcan.2020.05.031
10.1515/polyeng-2019-0265
10.1016/j.jpba.2018.07.025
10.1016/j.ijpharm.2020.119778
ContentType Journal Article
Copyright 2021 The Author(s)
2021 The Author(s) 2021
Copyright_xml – notice: 2021 The Author(s)
– notice: 2021 The Author(s) 2021
DBID 6I.
AAFTH
ADJCN
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.sjbs.2021.05.025
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2213-7106
EndPage 5073
ExternalDocumentID oai_doaj_org_article_419f09f94af041c09ef10ea9bd3bc849
10_1016_j_sjbs_2021_05_025
1410152
S1319562X21003934
GroupedDBID --K
0R~
0SF
123
1B1
4.4
457
5VS
6I.
71M
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AALRI
AAQFI
AAXUO
ABMAC
ACGFS
ADBBV
ADEZE
ADMUD
AENEX
AEXQZ
AFTJW
AGHFR
AITUG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BCNDV
DIK
E3Z
EBS
EJD
EP3
FDB
FEDTE
FNPLU
GROUPED_DOAJ
HVGLF
HYE
HZ~
IPNFZ
IXB
KQ8
M41
M~E
NCXOZ
O-L
O9-
OK1
OZT
RIG
ROL
RPM
SES
SSZ
XH2
~S-
AAHBH
ADJCN
ADVLN
AKRWK
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c521t-3f0b2bf5b48d61981611d483b42dafb3ce13986ef175b2e9580ff958dda115b03
IEDL.DBID RPM
ISSN 1319-562X
IngestDate Thu Jul 04 21:11:41 EDT 2024
Tue Sep 17 20:50:32 EDT 2024
Fri Aug 16 07:20:53 EDT 2024
Fri Aug 23 02:01:30 EDT 2024
Thu Sep 12 21:20:37 EDT 2024
Fri Feb 23 02:45:48 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Nanoparticles
PLGA
Chitosan
Gefitinib
MTT assay
Language English
License This is an open access article under the CC BY-NC-ND license.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c521t-3f0b2bf5b48d61981611d483b42dafb3ce13986ef175b2e9580ff958dda115b03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381081/
PMID 34466084
PQID 2568254281
PQPubID 23479
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_419f09f94af041c09ef10ea9bd3bc849
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8381081
proquest_miscellaneous_2568254281
crossref_primary_10_1016_j_sjbs_2021_05_025
emarefa_primary_1410152
elsevier_sciencedirect_doi_10_1016_j_sjbs_2021_05_025
PublicationCentury 2000
PublicationDate 2021-09-01
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-01
  day: 01
PublicationDecade 2020
PublicationPlace Riyadh, Saudi Arabia
PublicationPlace_xml – name: Riyadh, Saudi Arabia
PublicationTitle Saudi journal of biological sciences
PublicationYear 2021
Publisher Elsevier B.V
Saudi Biological Society
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Saudi Biological Society
– name: Elsevier
References Liu, Lin, Huang, Guan, Jiang (b0095) 2017; 20
Chen, Clauser, Thiebes, McGrath, Kelly, van Steenbergen, Jockenhoevel, Steinseifer, McHugh, Hennink, Kok (b0055) 2017; 103
Gidwani, Vyas, Kaur (b0070) 2018; 160
Arafa, Girgis, El-Dahan (b0035) 2020; 15
Chen, Xie, Qin, Jia, Cai, Nan, Yang, Lv, Zhang (b0050) 2016; 138
Zhang, Bao, Zhang (b0170) 2020; 101807
Quan, Chen, Wang (b0120) 2020; 495
Huang, Dai, Wen, Zhao, Wu, Zhou (b0080) 2020; 21
Shi, Su, Cui (b0130) 2014; 12
Cao, Hong, Cai (b0045) 2020; 173647
Gupta, Marwaha, Dureja (b0075) 2017; 5
Kocbek, Obermajer, Cegnar, Kos, Kristl (b0085) 2007; 120
Ahmed, Badr-Eldin (b0005) 2020; 588
Shukla, Jadaun, Arora, Sinha, Biyani, Jain (b0140) 2014; 2
Dyawanapelly, Koli, Dharamdasani, Jain, Dandekar (b0065) 2016; 6
Bouchnita, Volpert, Koury, Hellander (b0040) 2020; 319
Li, Wang, Li, Liu, Zheng, Zhang (b0090) 2019; 11
Ni, Chen, Zhang, Yang, Xu, Wu, Liu, Yang, Chen, Fu, Wu (b0115) 2017; 24
Yang, Jang, Lee, Kang, Lim (b0160) 2020; 146
Anwer, Al-Shdefat, Ezzeldin, Alshahrani, Alshetaili, Iqbal (b0020) 2017; 8
Rezvantalab, Drude, Moraveji, Güvener, Koons, Shi, Lammers, Kiessling (b0125) 2018; 9
Sun, Liu, Shao, Miao (b0145) 2015; 8
Dadwal, Baldi, Kumar Narang (b0060) 2018; 46
Allam, Aly, Farouk, El Kerdawy, Rashwan, Abbass (b0010) 2020; 98
Anzar, Mirza, Anwer, Khuroo, Alshetaili, Alshahrani, Meena, Hasan, Talegaonkar, Panda, Iqbal (b0030) 2018; 249
Alshdefat, Anwer, Fayed, Alsulays, Tawfeek, Abdel-Rahman, Soliman (b0015) 2020; 55
Anwer, Mohammad, Ezzeldin, Fatima, Alalaiwe, Iqbal (b0025) 2019; 14
Yang, Cheng, Murakami, Yang, He, Nakagawa, Kang, Kim, Hozak, nguyen, Zhang, Enatsu, Puri, Orlando (b0165) 2020; 15
Mohammed, Alnafisah, Anwer, Fatima, Almutairy, Alshahrani, Alshetaili, Alalaiwe, Fayed, Alanazi, Alzahrani, Hailat, Alshdefat (b0105) 2019; 39
Supramaniam, Adnan, Mohd Kaus, Bushra (b0150) 2018; 118
Xie, Gao, Wu (b0155) 2020; 159
Zhang, Wang, Li, Bao, Chen, Ge, Jin (b0175) 2020; 149
Nafee, Taetz, Schneider, Schaefer, Lehr (b0110) 2007; 3
Luo, Hua, Shang (b0100) 2021; 23
Shim, Yoo (b0135) 2020; 18
Ni (10.1016/j.sjbs.2021.05.025_b0115) 2017; 24
Shukla (10.1016/j.sjbs.2021.05.025_b0140) 2014; 2
Arafa (10.1016/j.sjbs.2021.05.025_b0035) 2020; 15
Shi (10.1016/j.sjbs.2021.05.025_b0130) 2014; 12
Sun (10.1016/j.sjbs.2021.05.025_b0145) 2015; 8
Dyawanapelly (10.1016/j.sjbs.2021.05.025_b0065) 2016; 6
Shim (10.1016/j.sjbs.2021.05.025_b0135) 2020; 18
Li (10.1016/j.sjbs.2021.05.025_b0090) 2019; 11
Alshdefat (10.1016/j.sjbs.2021.05.025_b0015) 2020; 55
Cao (10.1016/j.sjbs.2021.05.025_b0045) 2020; 173647
Quan (10.1016/j.sjbs.2021.05.025_b0120) 2020; 495
Rezvantalab (10.1016/j.sjbs.2021.05.025_b0125) 2018; 9
Huang (10.1016/j.sjbs.2021.05.025_b0080) 2020; 21
Anzar (10.1016/j.sjbs.2021.05.025_b0030) 2018; 249
Nafee (10.1016/j.sjbs.2021.05.025_b0110) 2007; 3
Gupta (10.1016/j.sjbs.2021.05.025_b0075) 2017; 5
Anwer (10.1016/j.sjbs.2021.05.025_b0025) 2019; 14
Liu (10.1016/j.sjbs.2021.05.025_b0095) 2017; 20
Bouchnita (10.1016/j.sjbs.2021.05.025_b0040) 2020; 319
Zhang (10.1016/j.sjbs.2021.05.025_b0175) 2020; 149
Dadwal (10.1016/j.sjbs.2021.05.025_b0060) 2018; 46
Yang (10.1016/j.sjbs.2021.05.025_b0165) 2020; 15
Supramaniam (10.1016/j.sjbs.2021.05.025_b0150) 2018; 118
Gidwani (10.1016/j.sjbs.2021.05.025_b0070) 2018; 160
Ahmed (10.1016/j.sjbs.2021.05.025_b0005) 2020; 588
Allam (10.1016/j.sjbs.2021.05.025_b0010) 2020; 98
Yang (10.1016/j.sjbs.2021.05.025_b0160) 2020; 146
Kocbek (10.1016/j.sjbs.2021.05.025_b0085) 2007; 120
Zhang (10.1016/j.sjbs.2021.05.025_b0170) 2020; 101807
Chen (10.1016/j.sjbs.2021.05.025_b0055) 2017; 103
Anwer (10.1016/j.sjbs.2021.05.025_b0020) 2017; 8
Luo (10.1016/j.sjbs.2021.05.025_b0100) 2021; 23
Chen (10.1016/j.sjbs.2021.05.025_b0050) 2016; 138
Mohammed (10.1016/j.sjbs.2021.05.025_b0105) 2019; 39
Xie (10.1016/j.sjbs.2021.05.025_b0155) 2020; 159
References_xml – volume: 2
  start-page: 27
  year: 2014
  end-page: 39
  ident: b0140
  article-title: In vitro toxicity assessment of chitosan oligosaccharide coated iron oxide nanoparticles
  publication-title: Toxicol. Rep.
  contributor:
    fullname: Jain
– volume: 173647
  year: 2020
  ident: b0045
  article-title: Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase
  publication-title: Eur. J. Pharmacol.
  contributor:
    fullname: Cai
– volume: 319
  year: 2020
  ident: b0040
  article-title: A multiscale model to design therapeutic strategies that overcome drug resistance to tyrosine kinase inhibitors in multiple myeloma
  publication-title: Math. Biosci.
  contributor:
    fullname: Hellander
– volume: 46
  start-page: 295
  year: 2018
  end-page: 305
  ident: b0060
  article-title: Nanoparticles as carriers for drug delivery in cancer
  publication-title: Artif. Cells Nanomed. Biotechnol.
  contributor:
    fullname: Kumar Narang
– volume: 11
  start-page: 469
  year: 2019
  ident: b0090
  article-title: Development and evaluation of multifunctional poly(lactic-co-glycolic acid) nanoparticles embedded in carboxymethyl β-glucan porous microcapsules as a novel drug delivery system for gefitinib
  publication-title: Pharmaceutics.
  contributor:
    fullname: Zhang
– volume: 9
  start-page: 1260
  year: 2018
  ident: b0125
  article-title: PLGA-based nanoparticles in cancer treatment
  publication-title: Front. Pharmacol.
  contributor:
    fullname: Kiessling
– volume: 39
  start-page: 909
  year: 2019
  end-page: 916
  ident: b0105
  article-title: Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer
  publication-title: J. Polym. Engn.
  contributor:
    fullname: Alshdefat
– volume: 14
  start-page: 1587
  year: 2019
  end-page: 1595
  ident: b0025
  article-title: Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and
  publication-title: Int. J. Nanomed.
  contributor:
    fullname: Iqbal
– volume: 160
  start-page: 31
  year: 2018
  end-page: 37
  ident: b0070
  article-title: Investigation of inclusion behaviour of gefitinib with epichlorohydrin-β-cyclodextrin polymer: preparation of binary complex, stoichiometric determination and characterization
  publication-title: J. Pharm. Biomed. Anal.
  contributor:
    fullname: Kaur
– volume: 20
  start-page: 43
  year: 2017
  end-page: 51
  ident: b0095
  article-title: Tailoring the particle microstructures of gefitinib by supercritical CO2 anti-solvent process
  publication-title: J. CO2 Util.
  contributor:
    fullname: Jiang
– volume: 21
  start-page: 885
  year: 2020
  end-page: 899
  ident: b0080
  article-title: circSETD3 contributes to acquired resistance to gefitinib in non-small-cell lung cancer by targeting the miR-520h/ABCG2 pathway
  publication-title: Mol. Ther - Nucleic Acids.
  contributor:
    fullname: Zhou
– volume: 5
  start-page: 301
  year: 2017
  end-page: 309
  ident: b0075
  article-title: Development and characterization of gefitinib loaded polymeric nanoparticles by ionic gelation method
  publication-title: Pharm. Nanotechnol.
  contributor:
    fullname: Dureja
– volume: 495
  start-page: 41
  year: 2020
  end-page: 52
  ident: b0120
  article-title: Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
  publication-title: Cancer Lett.
  contributor:
    fullname: Wang
– volume: 118
  start-page: 640
  year: 2018
  end-page: 648
  ident: b0150
  article-title: Magnetic nanocellulose alginate hydrogel beads as potential drug delivery system
  publication-title: Int. J. Biol. Macromol.
  contributor:
    fullname: Bushra
– volume: 8
  start-page: 844
  year: 2017
  ident: b0020
  article-title: Preparation, evaluation and bioavailability studies of eudragit coated PLGA nanoparticles for sustained release of eluxadoline for the treatment of irritable bowel syndrome
  publication-title: Front. Pharmacol.
  contributor:
    fullname: Iqbal
– volume: 588
  year: 2020
  ident: b0005
  article-title: Biodegradable self-assembled nanoparticles of PEG-PLGA amphiphilic diblock copolymer as a promising stealth system for augmented vinpocetine brain delivery
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Badr-Eldin
– volume: 15
  start-page: 1335
  year: 2020
  end-page: 1347
  ident: b0035
  article-title: Chitosan-coated PLGA nanoparticles for enhanced ocular anti-inflammatory efficacy of atorvastatin calcium
  publication-title: Int. J. Nanomed.
  contributor:
    fullname: El-Dahan
– volume: 6
  start-page: 365
  year: 2016
  end-page: 379
  ident: b0065
  article-title: Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins
  publication-title: Drug. Deliv. Trans. Res.
  contributor:
    fullname: Dandekar
– volume: 249
  start-page: 609
  year: 2018
  end-page: 616
  ident: b0030
  article-title: Preparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancer
  publication-title: J. Mol. Liq.
  contributor:
    fullname: Iqbal
– volume: 120
  start-page: 18
  year: 2007
  end-page: 26
  ident: b0085
  article-title: Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
  publication-title: J. Contrl. Rel.
  contributor:
    fullname: Kristl
– volume: 159
  start-page: 104934
  year: 2020
  ident: b0155
  article-title: Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway
  publication-title: Pharmacol. Res.
  contributor:
    fullname: Wu
– volume: 103
  start-page: 94
  year: 2017
  end-page: 103
  ident: b0055
  article-title: Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
  publication-title: Eur. J. Pharm. Sci.
  contributor:
    fullname: Kok
– volume: 3
  start-page: 173
  year: 2007
  end-page: 183
  ident: b0110
  article-title: Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides
  publication-title: Nanomed.
  contributor:
    fullname: Lehr
– volume: 18
  start-page: 605
  year: 2020
  ident: b0135
  article-title: The application of mucoadhesive chitosan nanoparticles in nasal drug delivery
  publication-title: Mar. Drugs
  contributor:
    fullname: Yoo
– volume: 146
  start-page: 70
  year: 2020
  end-page: 77
  ident: b0160
  article-title: AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation
  publication-title: Lung Cancer.
  contributor:
    fullname: Lim
– volume: 138
  start-page: 1
  year: 2016
  end-page: 9
  ident: b0050
  article-title: Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin
  publication-title: Colloids Surf. B, Biointerfaces.
  contributor:
    fullname: Zhang
– volume: 15
  start-page: 91
  year: 2020
  end-page: 100
  ident: b0165
  article-title: A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival and biomarker analysis
  publication-title: J. Thor. Oncol.
  contributor:
    fullname: Orlando
– volume: 12
  start-page: 43
  year: 2014
  ident: b0130
  article-title: Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells
  publication-title: J. Nanobiotechnol.
  contributor:
    fullname: Cui
– volume: 98
  year: 2020
  ident: b0010
  article-title: Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents
  publication-title: Bioorg. Chem.
  contributor:
    fullname: Abbass
– volume: 101807
  year: 2020
  ident: b0170
  article-title: Chemo-photodynamic therapy by pulmonary delivery of gefitinib nanoparticles and 5-aminolevulinic acid for treatment of primary lung cancer of rats
  publication-title: Photodiagn. Photodyn. Ther.
  contributor:
    fullname: Zhang
– volume: 8
  start-page: 19670
  year: 2015
  end-page: 19681
  ident: b0145
  article-title: Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer
  publication-title: Int. J. Clin. Expt. Med.
  contributor:
    fullname: Miao
– volume: 23
  start-page: 325
  year: 2021
  ident: b0100
  article-title: Application of nanotechnology in drug delivery systems for respiratory diseases (Review)
  publication-title: Mol. Med. Rep.
  contributor:
    fullname: Shang
– volume: 24
  start-page: 1501
  year: 2017
  end-page: 1512
  ident: b0115
  article-title: and
  publication-title: Drug Deliv.
  contributor:
    fullname: Wu
– volume: 149
  year: 2020
  ident: b0175
  article-title: Comparative study of intratracheal and oral gefitinib for the treatment of primary lung cancer
  publication-title: Eur. J. Pharm. Sci.
  contributor:
    fullname: Jin
– volume: 55
  year: 2020
  ident: b0015
  article-title: Preparation and evaluation of spray dried rosuvastatin calcium-PVP microparticles for the improvement of serum lipid profile
  publication-title: J. Drug. Deliv. Sci. Technol.
  contributor:
    fullname: Soliman
– volume: 9
  start-page: 1260
  year: 2018
  ident: 10.1016/j.sjbs.2021.05.025_b0125
  article-title: PLGA-based nanoparticles in cancer treatment
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.01260
  contributor:
    fullname: Rezvantalab
– volume: 6
  start-page: 365
  year: 2016
  ident: 10.1016/j.sjbs.2021.05.025_b0065
  article-title: Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins
  publication-title: Drug. Deliv. Trans. Res.
  doi: 10.1007/s13346-016-0295-x
  contributor:
    fullname: Dyawanapelly
– volume: 103
  start-page: 94
  year: 2017
  ident: 10.1016/j.sjbs.2021.05.025_b0055
  article-title: Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2017.02.002
  contributor:
    fullname: Chen
– volume: 149
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0175
  article-title: Comparative study of intratracheal and oral gefitinib for the treatment of primary lung cancer
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2020.105352
  contributor:
    fullname: Zhang
– volume: 18
  start-page: 605
  issue: 12
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0135
  article-title: The application of mucoadhesive chitosan nanoparticles in nasal drug delivery
  publication-title: Mar. Drugs
  doi: 10.3390/md18120605
  contributor:
    fullname: Shim
– volume: 21
  start-page: 885
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0080
  article-title: circSETD3 contributes to acquired resistance to gefitinib in non-small-cell lung cancer by targeting the miR-520h/ABCG2 pathway
  publication-title: Mol. Ther - Nucleic Acids.
  doi: 10.1016/j.omtn.2020.07.027
  contributor:
    fullname: Huang
– volume: 495
  start-page: 41
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0120
  article-title: Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.09.003
  contributor:
    fullname: Quan
– volume: 101807
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0170
  article-title: Chemo-photodynamic therapy by pulmonary delivery of gefitinib nanoparticles and 5-aminolevulinic acid for treatment of primary lung cancer of rats
  publication-title: Photodiagn. Photodyn. Ther.
  contributor:
    fullname: Zhang
– volume: 3
  start-page: 173
  issue: 3
  year: 2007
  ident: 10.1016/j.sjbs.2021.05.025_b0110
  article-title: Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides
  publication-title: Nanomed.
  doi: 10.1016/j.nano.2007.03.006
  contributor:
    fullname: Nafee
– volume: 173647
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0045
  article-title: Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase
  publication-title: Eur. J. Pharmacol.
  contributor:
    fullname: Cao
– volume: 118
  start-page: 640
  year: 2018
  ident: 10.1016/j.sjbs.2021.05.025_b0150
  article-title: Magnetic nanocellulose alginate hydrogel beads as potential drug delivery system
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2018.06.043
  contributor:
    fullname: Supramaniam
– volume: 15
  start-page: 91
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0165
  article-title: A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival and biomarker analysis
  publication-title: J. Thor. Oncol.
  doi: 10.1016/j.jtho.2019.09.008
  contributor:
    fullname: Yang
– volume: 20
  start-page: 43
  year: 2017
  ident: 10.1016/j.sjbs.2021.05.025_b0095
  article-title: Tailoring the particle microstructures of gefitinib by supercritical CO2 anti-solvent process
  publication-title: J. CO2 Util.
  doi: 10.1016/j.jcou.2017.04.015
  contributor:
    fullname: Liu
– volume: 2
  start-page: 27
  year: 2014
  ident: 10.1016/j.sjbs.2021.05.025_b0140
  article-title: In vitro toxicity assessment of chitosan oligosaccharide coated iron oxide nanoparticles
  publication-title: Toxicol. Rep.
  doi: 10.1016/j.toxrep.2014.11.002
  contributor:
    fullname: Shukla
– volume: 8
  start-page: 19670
  issue: 10
  year: 2015
  ident: 10.1016/j.sjbs.2021.05.025_b0145
  article-title: Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer
  publication-title: Int. J. Clin. Expt. Med.
  contributor:
    fullname: Sun
– volume: 159
  start-page: 104934
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0155
  article-title: Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2020.104934
  contributor:
    fullname: Xie
– volume: 14
  start-page: 1587
  year: 2019
  ident: 10.1016/j.sjbs.2021.05.025_b0025
  article-title: Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S195048
  contributor:
    fullname: Anwer
– volume: 11
  start-page: 469
  year: 2019
  ident: 10.1016/j.sjbs.2021.05.025_b0090
  article-title: Development and evaluation of multifunctional poly(lactic-co-glycolic acid) nanoparticles embedded in carboxymethyl β-glucan porous microcapsules as a novel drug delivery system for gefitinib
  publication-title: Pharmaceutics.
  doi: 10.3390/pharmaceutics11090469
  contributor:
    fullname: Li
– volume: 15
  start-page: 1335
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0035
  article-title: Chitosan-coated PLGA nanoparticles for enhanced ocular anti-inflammatory efficacy of atorvastatin calcium
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S237314
  contributor:
    fullname: Arafa
– volume: 120
  start-page: 18
  year: 2007
  ident: 10.1016/j.sjbs.2021.05.025_b0085
  article-title: Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
  publication-title: J. Contrl. Rel.
  doi: 10.1016/j.jconrel.2007.03.012
  contributor:
    fullname: Kocbek
– volume: 319
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0040
  article-title: A multiscale model to design therapeutic strategies that overcome drug resistance to tyrosine kinase inhibitors in multiple myeloma
  publication-title: Math. Biosci.
  doi: 10.1016/j.mbs.2019.108293
  contributor:
    fullname: Bouchnita
– volume: 98
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0010
  article-title: Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents
  publication-title: Bioorg. Chem.
  doi: 10.1016/j.bioorg.2020.103726
  contributor:
    fullname: Allam
– volume: 138
  start-page: 1
  year: 2016
  ident: 10.1016/j.sjbs.2021.05.025_b0050
  article-title: Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin
  publication-title: Colloids Surf. B, Biointerfaces.
  doi: 10.1016/j.colsurfb.2015.11.033
  contributor:
    fullname: Chen
– volume: 24
  start-page: 1501
  year: 2017
  ident: 10.1016/j.sjbs.2021.05.025_b0115
  article-title: In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
  publication-title: Drug Deliv.
  doi: 10.1080/10717544.2017.1384862
  contributor:
    fullname: Ni
– volume: 55
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0015
  article-title: Preparation and evaluation of spray dried rosuvastatin calcium-PVP microparticles for the improvement of serum lipid profile
  publication-title: J. Drug. Deliv. Sci. Technol.
  contributor:
    fullname: Alshdefat
– volume: 23
  start-page: 325
  year: 2021
  ident: 10.1016/j.sjbs.2021.05.025_b0100
  article-title: Application of nanotechnology in drug delivery systems for respiratory diseases (Review)
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2021.11964
  contributor:
    fullname: Luo
– volume: 46
  start-page: 295
  year: 2018
  ident: 10.1016/j.sjbs.2021.05.025_b0060
  article-title: Nanoparticles as carriers for drug delivery in cancer
  publication-title: Artif. Cells Nanomed. Biotechnol.
  doi: 10.1080/21691401.2018.1457039
  contributor:
    fullname: Dadwal
– volume: 12
  start-page: 43
  year: 2014
  ident: 10.1016/j.sjbs.2021.05.025_b0130
  article-title: Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells
  publication-title: J. Nanobiotechnol.
  doi: 10.1186/s12951-014-0043-7
  contributor:
    fullname: Shi
– volume: 8
  start-page: 844
  year: 2017
  ident: 10.1016/j.sjbs.2021.05.025_b0020
  article-title: Preparation, evaluation and bioavailability studies of eudragit coated PLGA nanoparticles for sustained release of eluxadoline for the treatment of irritable bowel syndrome
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00844
  contributor:
    fullname: Anwer
– volume: 249
  start-page: 609
  year: 2018
  ident: 10.1016/j.sjbs.2021.05.025_b0030
  article-title: Preparation, evaluation and pharmacokinetic studies of spray dried PLGA polymeric submicron particles of simvastatin for the effective treatment of breast cancer
  publication-title: J. Mol. Liq.
  doi: 10.1016/j.molliq.2017.11.081
  contributor:
    fullname: Anzar
– volume: 146
  start-page: 70
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0160
  article-title: AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation
  publication-title: Lung Cancer.
  doi: 10.1016/j.lungcan.2020.05.031
  contributor:
    fullname: Yang
– volume: 39
  start-page: 909
  year: 2019
  ident: 10.1016/j.sjbs.2021.05.025_b0105
  article-title: Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer
  publication-title: J. Polym. Engn.
  doi: 10.1515/polyeng-2019-0265
  contributor:
    fullname: Mohammed
– volume: 160
  start-page: 31
  year: 2018
  ident: 10.1016/j.sjbs.2021.05.025_b0070
  article-title: Investigation of inclusion behaviour of gefitinib with epichlorohydrin-β-cyclodextrin polymer: preparation of binary complex, stoichiometric determination and characterization
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2018.07.025
  contributor:
    fullname: Gidwani
– volume: 5
  start-page: 301
  year: 2017
  ident: 10.1016/j.sjbs.2021.05.025_b0075
  article-title: Development and characterization of gefitinib loaded polymeric nanoparticles by ionic gelation method
  publication-title: Pharm. Nanotechnol.
  contributor:
    fullname: Gupta
– volume: 588
  year: 2020
  ident: 10.1016/j.sjbs.2021.05.025_b0005
  article-title: Biodegradable self-assembled nanoparticles of PEG-PLGA amphiphilic diblock copolymer as a promising stealth system for augmented vinpocetine brain delivery
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2020.119778
  contributor:
    fullname: Ahmed
SSID ssj0068381
Score 2.456354
Snippet In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA nanoparticles (GFT-CS-PLGA-NPs) were synthesized to...
SourceID doaj
pubmedcentral
proquest
crossref
emarefa
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Publisher
StartPage 5065
SubjectTerms Chitosan
Gefitinib
MTT assay
Nanoparticles
Original
PLGA
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQpUpcEJQtLJWRuKEIJ7ET5_hAXYQAcaDSu1leS6rWqfpSiUr98Z2JE_pygQuXHGJnmSX2N_H4G0LeW2-NBRieW21dzitvc90ElsNg6WqsCOcF7kb-9r0-PuFf1mK9VeoLc8ISPXBS3EdetIG1oeU6MF5Y1vpQMK9b4ypjJU9b9woxB1NpDK5lJVOoVbQ5zPDrabtMyuzanBkk6i6LkbMTi2RvTUkjc_9iZtr1Fxqa9AKDLjMot6akw8fk0YQl6SrJ8IQ88HGP7KbqkjdPye2RD93Qxc7Q81477-iPr0crqqOjuHjQb3SktgesOTVEHSGCnhLlKP6gpRf6NHYBUCq1N0M_9L87C6id6lPdAaykKwj76DkMF9Si81xRXAagCFw3z8jJ4cHPz8f5VGwht1jTIK8CM6UJwnAJRmolIMHCcVkZXjodTGU9YEVZg_YbYUrfCslCgKNzGtRvWPWc7MQ--peE8lrK0AZeI_dgJY0J1jMNOFI7Y13TZOTDrG91mTg11JxsdqbQOgqto5hQYJ2MfEKT_OmJfNjjCfASNSlF_ctLMiJmg6oJWiTIALfq_vrwF5P179-UQ19RZuTd7A0KvkjUr46-v4bLRY1hdymLjDQLN1nIsGyJ3a-R2xsdF1Daq_8h9GvyEEVJGXFvyM5wde3fAoQazP74tdwBQDAa3g
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Elsevier Free Content
  dbid: IXB
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhEOil9F23aVGht2JWtmWvdNyEJqG0pdAG9ib03Dokcth1oIH8-M7YchtfeujFYEu2Zc149I098w0h7623xgIMz622LueVt7leBpaDsXQNVoTzNWYjf_nanJ3zT-t6vUeOp1wYDKtMtn-06YO1TkcWaTYX1227-F5UmOtWrsFpwQRT5ARFbk9M4lsfTda4EZUYna5C5tg7Jc6MMV67C4OU3WUxsHdiuex7i9PA4T9bow78lYYmPUOj81jKe4vTySPyMKFKuhoH_pjs-fiEHIx1Jm-fkrtTH9q-ja2hl5123tFvn09XVEdH8TdCt9OR2g5QZ2qIOoIvnULmKH6qpVd6E9sAeJXa277ru1-tBfxO9Ua3ADDpChxAegmGg1pUoy3FHwIUIezuGTk_-fjj-CxPZRdyi9UN8iowU5pQGy5AXFIAJiwcF5XhpdPBVNYDahSND4A8TOllLVgIsHVOA7w0rHpO9mMX_UtCeSNEkIE3yEJYCWOC9UwDotTOWLdcZuTDNN_qemTXUFPY2YVC6SiUjmK1Aulk5AhF8qcnMmMPB7rtRqVJUbyQgckguQ6MF5ZJGCfzWhpXGSu4zEg9CVTNFA0u1f7z5i-S9P-OlEPfuszIu0kbFLybOL86-u4GTq8bdMBLUWRkOVOT2TPMW2L7c2D5RsUFvPbqP8f7mjzAvTEc7pDs99sb_wbwU2_eDi_Ib89JGug
  priority: 102
  providerName: Elsevier
Title Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines
URI https://dx.doi.org/10.1016/j.sjbs.2021.05.025
https://search.emarefa.net/detail/BIM-1410152
https://search.proquest.com/docview/2568254281
https://pubmed.ncbi.nlm.nih.gov/PMC8381081
https://doaj.org/article/419f09f94af041c09ef10ea9bd3bc849
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJINBL6btO2qBCb8VZ2ZZt6bgJebR0Sw4N7M3ouXXYlcPuBhoI_e2d8aONLz30ooMl2bJmJH0jjb4h5KNxRhuA4bFRxsY8cyZWpWcxTJa2wIhwLsfbyLNvxeU1_zLP5zskH-7CtE77RtfHYbk6DvWP1rfydmUmg5_Y5Gp2KpCWSiSTXbJbZtlgonfTb4GZrZWVyBgW93l_U6Zz6trcaOToTpOWrjPFuDUZnmi27KaPFqaWv3-0Pu27lYIsNUKiYz_KRwvT-TPytEeUdNq1_DnZceEF2e9iTN6_JA8XztfbOtSaLhtlnaVXXy-mVAVL8Qih2ahATQOIs88IKoAd3XcDxW1aulKLUHvAqtTcb5tt87M2gN2pWqgawCWdgvFHlzBpUIMqtKZ4GEARvm5ekevzs--nl3EfciE2GNkgzjzTqfa55gJEJQXgwcRykWmeWuV1ZhwgRlE4D6hDp07mgnkPqbUKoKVm2WuyF5rg3hLKCyG89LxABsJMaO2NYwrQpLLa2LKMyKehv6vbjlmjGlzObioUVIWCqlhegaAicoIi-VMSWbHbB816UfWdUvFEeia95MoznhgmoZ3MKaltpo3gMiL5INCqBxgdcIBX1f_8-Jte-n9byqFsnkbkw6ANFYxL7F8VXHMH1fMCje9UJBEpR2oy-odxDih8y_DdK_jBf9c8JE-w_Z0z3Duyt13fufeAnrb6qN11gPTz_ATS2a-zo3b8_AYXGx38
link.rule.ids 230,315,733,786,790,870,891,2115,3525,27957,27958,45909,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKUQUX3oXlaSRuKLt5OFnnuFS0C-xWPbSoN8vPJWXXqXazEkX8eGbygIYDElxyyMRxnHy2v4nH3xDyRlutNNDwQEttApZYHcixCwMYLE2GGeFsiruR58fZ9Ix9PE_Pd0ja7YWpg_a1KoZ-uRr64ksdW3m50qMuTmx0Mj_gKEvFo9ENchP6azzunPRmAM7QXPtZUR7A9H7e7pVpwro2FwpVuuOoFuyMMXNNgmuatb7ptampVvDvzVB7diXBJHtctB9JeW1qOrxLPneNaiJSvg63lRrq73_oPf5zq--ROy1ZpZPGfJ_sWP-A7DXpK68ekh9H1hVV4QtFl6U01tCT2dGESm8ork6UG-mpLoHMtgYvPbjobV0U_wDTlVz4wgENpvqqKqvyW6HBLaByIQvgrXQCfiVdwnhENaJzTXGdgSIz3jwiZ4fvTw-mQZvNIdCYNCFIXKhi5VLFOKAg50A1I8N4olhspFOJtkBGeWYdEBoV2zzloXNwNEYCa1Vhsk92fentE0JZxrnLHctQ3DDhSjltQwlEVRqlzXg8IG-7DykuG9EO0UWzXQhEgEAEiDAVgIABeYff-teVKLhdnyjXC9G-FMGi3IW5y5l0IYt0mMNzhlbmyiRKc5YPSNohRbTcpeEkcKvir5U_bmH1-0kZXJvGA_K6g5mALo_vV3pbbqF4mqFfH_NoQMY9_PXa0LcAqmrx8BZFT_-75Ctya3o6n4nZh-NPz8htbEsTc_ec7FbrrX0BJK1SL-su-RPNlzzH
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLZg0CAu7DBhNRI3lDaLk9rHMtAZYGbUAyNVXCyvJTOtU7WpxCB-PM9ZoOHAYS45xC-J7Xy2vxe_fA-ht8ooqYCGh0ooHZLUqFCMbBTCZKlznxHOZP5v5NOz_PicfJ5ls51UX3XQvpLFwC2WA1d8r2MrV0s17OLEhtPTQ-plqWg8XGk7vIluwZhNWOeoN5Nw7k1qXytmISzxs_Z_mSa0a3MhvVJ3EteinYnPXpP6fc1a43RneapV_Hur1L5ZCigSPT7aj6bcWZ4m99C3rmFNVMrlYFvJgfr5j-bjtVp-H91tSSseNyYP0A3jHqL9Jo3l1SP068jYoipcIfGiFNpoPD05GmPhNPa7FOVGOKxKILVtgRMOXPX2edh_CcZLMXeFBTqM1VVVVuWPQoF7gMVcFMBf8Rj8S7yAeQkrj9I19vsN2DPkzWN0Pvn49fA4bLM6hMonTwhTG8lE2kwSCmhgFChnrAlNJUm0sDJVBkgpzY0FYiMTwzIaWQtHrQWwVxmlT9CeK505QJjklFpmSe5FDlMqpVUmEkBYhZZKj0YBete9TL5qxDt4F9V2wT0KuEcBjzIOKAjQe_--_1h64e36RLme87ZTOImZjZhlRNiIxCpiUM_ICCZ1KhUlLEBZhxbecpiGm8Ctiv8-_GkLrb81JWCbJQF600GNw9D3_SucKbdweZZ7_z6hcYBGPQz22tAvAWTVIuItkp5d-8rX6Pb0w4SffDr78hzd8U1pQu9eoL1qvTUvgatV8lU9Kn8DoBI_Rw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gefitinib+loaded+PLGA+and+chitosan+coated+PLGA+nanoparticles+with+magnified+cytotoxicity+against+A549+lung+cancer+cell+lines&rft.jtitle=Saudi+journal+of+biological+sciences&rft.au=Alshetaili%2C+Abdullah+S.&rft.date=2021-09-01&rft.pub=Elsevier&rft.issn=1319-562X&rft.eissn=2213-7106&rft.volume=28&rft.issue=9&rft.spage=5065&rft.epage=5073&rft_id=info:doi/10.1016%2Fj.sjbs.2021.05.025&rft_id=info%3Apmid%2F34466084&rft.externalDBID=PMC8381081
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1319-562X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1319-562X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1319-562X&client=summon